Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very surprised that GDR only have 1million in sales arranged thus far. Was an investor here and I believe the product is a top one. Sales team need a rocket. Fortunes could very well turn around when second wave becomes evidential. GL to all who still hold here, hope they land some juicy contracts.
due a tick up
can sell at 88
Nio... is the ticker...
Can we not go back to discussing other stocks on this board. Pathetic enough today.
@ST sorry for the off agenda, but what's the ticker please for NIO? Which market etc?
It's AVCT that the comparison will be made with as they are behind us in terms of progress.
You will notice though how we are undervalued compared to AVCT rather than AVCT being overvalued compared to us.
You say GDR is undervalued compared to NCYT as its a 1/4 of its market cap - but GDR have sales orders for 1m NCYT has sales orders upto end of May of £120m - probably more like £160m now. Its valuation isn't comparing mcap to its peers its comparing its potential and sales to its peers. When you look at it objectively GDR doesn't seem undervalued at all.
@RM, that is a shame. GDR have a test for a disease that is growing and a proven POC platform to take testing out of the laboratory, hitting the market on multiple fronts. I don't see anyone else with the same offer. My view. I hold my shares long term in whatever I invest in, I understand others have a more transient share strategy.
Agree teabiscuit. Think there are a few hoping that, if things go 100% in GDR's favour, then this might be a good bet. When you've believed for so long, it's difficult to take an objective view. However, the facts are that we're in the midst of a raging Covid pandemic and GRD have STILL not generated sales (indicative doesn't count). Big tenders underway now that they're going to miss. By the time they have approvals, the cake will have been shared out. I'm staying in Covid, but not in GDR.
@Teabiscuit, afraid I agree. I fear I am getting ready to bail or at least halve, and put what's left of my £ in something else.
So they had CE approval and were expecting g significant sales in june. They didnt put applications for Fda and india approval in till mid june so it's clear db was expecting sales in eu or uk. The flaw in the plan was the whole of the eu has said nope we already have tests sorted thanks. The reality is that we could have made sales in europe as soon as that ce approval was given but the sales team were clearly slow off the mark and didnt have any pre-orders arranged for eu countries before eu approval. I suspect gdr have been shocked by how hard it is to sell their product. They may have a gold standard product but it is a sea of 100's of available tests and so far the gdr sales team are not up to the task of making the product stand out. Its poor from gdr and have cost shareholders. However I'd say now is a good buy in point if you are willing to wait a few months there is a chance this could still be turned around if india and america can provide exceptional results. Final note is they clearly have enough capacity to meet the demand for the gdr product. Overall I'm not that impressed with progress made since may and I dont want to keep hearing excuses about approvals, why did it take them so long to get the approvals process started for Fda and india....
CocaCola
Last word not needed. My previous post still stands.
______
CocaCola
And the part you're conveniently choosing to ignore is that GDR have a test to sell and are starting to sell it.
As such, given the market prices ahead, GDR is hugely undervalued in my opinion at only a quarter of NCYT's valuation and only a sixth of AVCT's valuation, who incidentally don't even have a test produced to sell yet, which shoots your whole argument in the foot.
It is very simple - our target markets (India and US) require approvals to sell.
Once our temp insensitive, easy to use (including improved simplified software add on) rapid turnaround (i.e. 90 min result determination) has bee approved - which is imminent this could easily return to 150p which is £75M and orders will roll. Massive month coming up!!
150p the sell zone. 90p the buy. Simples
I've had my Covid money spread over a few, inc GDR, but CCK is right. The market is now looking for cash generators (as am I), not jam tomorrow promises. At this stage, if all GDR can shout about is 1M in 'indicative sales', then I fear they've missed the boat. By the time they have their approvals, the cake will have been shared out. Others, such as NCYT, are making money now and have proven customers around the globe that are buying now. GDR does not.
@ RollingInIt
Nearly Covid plays at this stage has some form of test or treatment to sell. Some approved some not. Nothing profound about that, it's a given.
That stage is gone. It's about revenue.
Look at all the Covid charts. All downtrending except big cash generators.
Look, I only posted in here because there was some nonsense talked about GDR being where NCYT ignoring the entire landscape in the market which has changed over the past 3 months. It's misleading and I hope no new investor throws cash at something without thinking clearly about the bigger picture and checking whether the stock is up or downtrending and why.
I will stop posting and let you have the last word as it's ugly to stick the boot in when a stock isn't doing well, but it's also unfair to mislead fellow investors.
CocaCola
And the part you're conveniently choosing to ignore is that GDR have a test to sell and are starting to sell it.
As such, given the market prices ahead, GDR is hugely undervalued in my opinion at only a quarter of NCYT's valuation and only a sixth of AVCT's valuation, who incidentally don't even have a test produced to sell yet, which shoots your whole argument in the foot.
@RollingInIt
'Starting to do' is essentially meaningless at this stage when you have plays like NCYT making 30 million a month, and possibly hitting 50 million a month with new products about to hit the market like the winter test kits, mobile testing etc. Existing government contracts, big Pharma partnerships etc.
Think about what you're saying. Even if you believe, the market only cares for solid sales now. The race began months ago.
Looks at the charts. Look what's downtrending. Look what's reversing.
Most Covid stocks will sink, and only a few with huge sales will take the market's cash.
@ RollingInit
Please re-read my comment, it seems you and another poster is misinterpreting the entire context over the use of the term Covid bubble.
Covid bubble refers to the baked in valuations of Covid stocks as they peaked without actual cash generation. Hence the downtrend since. Check all Covid stocks. Nearly all have peaked and downtrended without any reversal in sight (except NCYT which has reversed for 3 weeks now up nearly 25 to 30% since the reversal).
Only cash generating Covid stocks which can show orders 6 to 12 months ahead will take cash now from the market.
Bubble has popped, we know Covid will stay, but it's about WHO is getting the cash.
."Money now goes into cash generators."
Which is exactly what GDR are starting to do and they're valued at four times less than NCYT.
*I'm looking to grow my account, NOT take a bet.
That should have read as.
@Blustington
The Covid bubble refers to the baked in valuations of Covid stocks which potentially could have generated large sales. That's why most Covid plays have large peaks and have downtrended since as sentiment began to wane over the longevity of those sales.
At this stage we have seen market confidence return that Covid testing will have some longevity as the cases have increased, but the market is more astute now, they're hunting for actual revenue in the half-yearly results in July and August.
Anyone not doing millions per month in sales will suffer. NCYT is already way past that stage. There is an expectation of 30 to 50 million per month. If that is confirmed then it will take most of the Covid FTSE small cap market share and be back to its peak.
Anything else will be left floundering.
I wa also heavily invested in a few Covid stocks, ODX for example for a while. But I'm not religious. If a stock doesn't generate cash compared to its rivals, why would my money be in there. I'm looking to grow my account, but take a bet.
The betting stage for Covid stocks was 3 months ago. Money now goes into cash generators.
CocaCola
Disagree..
At the time, there were 75,000 new cases daily, now nearing 250,000
Demand for testing is increasing globally.
https://www.worldometers.info/coronavirus/
You're living in a misled Uk view of Coronavirus.
covid bubble!? Covid is not gone I currently live in Cebu the phillipines and we have not left our condo for almost 4 months with cases rising daily. India our target market has an exponetial and out of control rise of cases. you are the one living in a Bubble!
@RollingInit
That's highly misleading.
NCYT started much earlier in the pandemic at the beginning of the Covid bubble.
Look at all the Covid stocks, they're nearly all downtrending since their peaks (GDR especially so). The market no longer cares for potential, the market needs to see actual revenue for the downtrending to reverse. NCYT has reversed for 3 weeks now and can continue to do so as it haas extraordinary sales figures.
NCYT is the opposite of most Covid stocks. It's undervalued by market cap compared to sales. That's because the market was unsure if Covid was here to stay as the lockdowns began to ease. Now we're seeing confidence return to biotech but only the top players with big sales coming in each month.
To compare GDR today to NCYT at the beginning of the crisis is disingenuous and misleading. The context is entirely different now.
samolly2
GDR have a superior product with better results. The more complex something is (even though this is simple to use) the longer it takes to line all the ducks up..New distribution, training, production, let alone all quality marks. The list is endless
As I said this can all change next week...all it takes is one area to approve and the others will all start to fall in line. The money is there to support it too.
Yeah good post guys, almost the same as NCYT.
Except for NCYT that was actual sales. Oh and they came 2 weeks after CE marking.
Almost the same.